TY - BOOK AU - Alzeer, Ali Hazem AU - Zaemes, Jacob TI - A patient with melanoma that became sensitized to immunotherapy after treatment with a CDK4/6 inhibitor SN - 1750-743X PY - 2020/// KW - *Antibodies, Monoclonal, Humanized/tu [Therapeutic Use] KW - *Antineoplastic Agents/tu [Therapeutic Use] KW - *Imidazoles/tu [Therapeutic Use] KW - *Immunotherapy/mt [Methods] KW - *Melanoma/dt [Drug Therapy] KW - *Oximes/tu [Therapeutic Use] KW - *Pyridones/tu [Therapeutic Use] KW - *Pyrimidinones/tu [Therapeutic Use] KW - Antibodies, Monoclonal, Humanized/im [Immunology] KW - Antineoplastic Agents/im [Immunology] KW - Cyclin-Dependent Kinase 4/ai [Antagonists & Inhibitors] KW - Cyclin-Dependent Kinase 4/im [Immunology] KW - Cyclin-Dependent Kinase 6/ai [Antagonists & Inhibitors] KW - Cyclin-Dependent Kinase 6/im [Immunology] KW - Humans KW - Imidazoles/im [Immunology] KW - Male KW - Melanoma/im [Immunology] KW - Middle Aged KW - Oximes/im [Immunology] KW - Pyridones/im [Immunology] KW - Pyrimidinones/im [Immunology] KW - Treatment Outcome KW - MedStar Washington Hospital Center KW - Internal Medicine Residency KW - Pathology Residency KW - Journal Article N2 - Background: Despite the profound effect that checkpoint inhibitors and BRAF/MEK inhibitors have had on survival in patients with metastatic melanoma, treatment options remain limited for those who demonstrate poor response or develop resistance to these modalities. The prospect of tumor sensitization to these treatments is therefore an attractive one. Results: We describe the case of a patient who developed a sustained response to trametinib and pembrolizumab, despite prior resistance to both these therapies, after receiving treatment with a CDK4/6 inhibitor. Discussion: We further outline the preclinical data supporting a possible role for the use of CDK4/6 inhibitors in tumor sensitization to immunotherapy UR - https://dx.doi.org/10.2217/imt-2020-0139 ER -